Physician

Nabiel Alkhouri, M.D.

According to 2025 Medicare claims, Nabiel Alkhouri, M.D. (NPI: 1497728489) practices hematology/oncology in the Wheeling, WV-OH market, with the plurality of this provider's patient population coming from Marshall, WV. This provider's primary affiliated billing organization is REYNOLDS MEMORIAL HOSPITAL, INC (NPI: 1518068014; TIN: 550357045) and primary practice location at 26038-1407. Alkhouri is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Alkhouri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 292 traditional Medicare patients, billed 656 HCPCS/CPT codes, and received $62,012 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,272 prescription claims across 174 beneficiaries totaling $1,909,354 in drug costs, led by Pomalyst (Pomalidomide). 2016 DME data shows 107 claims. Open Payments data shows 2 records totaling $120. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $499,055 to $1,909,354. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	180	909	$60,962
2016	231	879	$62,006
2017	222	683	$49,066
2018	81	370	$31,015
2019	138	476	$38,158
2020	122	155	$12,460
2021	120	145	$11,973
2022	269	475	$49,744
2023	301	683	$64,000
2024	292	656	$62,012

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	123	1,023	$499,055
2016	136	1,146	$441,453
2017	127	1,103	$286,795
2018	56	305	$28,432
2019	112	733	$730,434
2020	161	989	$2,118,433
2021	185	1,265	$2,449,695
2022	172	1,201	$1,909,642
2023	195	1,342	$1,508,071
2024	174	1,272	$1,909,354

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	143	$31,938
2016	N/R	107	$5,162
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	28	28	$141
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	233	457	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	91	100	$74
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	39	52	$22
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	11	11	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	21	588	$493,409
Calquence	Acalabrutinib Maleate	16	480	$218,940
Brukinsa	Zanubrutinib	14	420	$210,742
Imbruvica	Ibrutinib	11	308	$179,686
Sandostatin Lar Depot	Octreotide Acetate,mi-Spheres	13	390	$118,642

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$120	Incyte Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nabiel Alkhouri, M.D.?

Tedicare shows public-source Medicare data for Nabiel Alkhouri, M.D. (NPI 1497728489), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nabiel Alkhouri, M.D. have ACO affiliation data?

Nabiel Alkhouri, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Nabiel Alkhouri, M.D.?

Nabiel Alkhouri, M.D. is linked to REYNOLDS MEMORIAL HOSPITAL, INC (billing NPI 1518068014) in the available physician profile data.

Does Nabiel Alkhouri, M.D. have Open Payments data?

Nabiel Alkhouri, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.